Part 9/13:
Investors are also considering sectors less susceptible to regulatory interference. Healthcare, notably medical services and biotech, could benefit from increased demand driven by China’s expanding middle class. Similarly, consumer staples and general consumption products are viewed as relatively resilient, given the government’s focus on economic stability and social policy objectives.